Bicalutamide News and Research

RSS

The efficacy and safety of anti-androgens in the management of hormonal and clinical features of PCOS

The safety and efficacy of anti-androgens in managing polycystic ovary syndrome (PCOS).

1 Sep 2023

New androgen biosynthesis inhibitor drug for prostate cancer shows mixed results

A new androgen biosynthesis inhibitor drug improved progression-free survival in prostate cancer but did not improve overall survival compared to current therapies, according to a study published in the Journal of Clinical Oncology.

31 May 2022

Researchers find novel inhibitors that may suppress oncogenesis of metastatic prostate cancer

Researchers have found that treating prostate cancer cells with novel cyclin-dependent kinase 19 (CDK19) and homologous cyclin-dependent kinase 8 (CDK8) inhibitors reduces their potential to migrate into and invade surrounding structures.

13 Apr 2022

Anti-androgen therapy for patients with advanced prostate cancer may fuel bone metastasis

Dr Bock, under the mentorship of Distinguished Professor Dietmar Hutmacher, from QUT Centre for Biomedical Technologies, has focused her research on bone metastases from breast and prostate cancers.

7 Jul 2021

SWOG researchers to present practice-changing research at virtual ASCO 2021

"SWOG always brings an impressive portfolio of work to the ASCO annual meeting," said SWOG Chair Charles D. Blanke, MD, "and this year I'm particularly excited about the research our investigators are presenting because it includes results that are likely to be practice-changing."

1 Jun 2021

Genomic test may help guide treatment decisions for patients with recurrent prostate cancer

A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers.

11 Feb 2021

Long-term hormone therapy does more harm than good for men with low PSAs after prostate surgery

A secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer finds long-term hormone therapy does more harm than good for many men and calls for rethinking treatment guidelines based on a patient's post-operative prostate-specific antigen (PSA) level.

26 Sep 2019

Pre-SRT PSA could serve as prognostic and predictive biomarker of benefit from hormone therapy

Initial results of NRG Oncology Clinical Trial RTOG 9601 in men with biochemically recurrent prostate cancer receiving salvage radiotherapy demonstrated improvement in OS from the addition of long-term hormone therapy to SRT.

17 Sep 2019

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

27 Jan 2016

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma Inc. and Medivation, Inc. today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer.

2 Apr 2015

Androgen receptor in prostate cancer cells can activate different gene set when bound to antiandrogens

The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

28 Jan 2015

Radiation plus hormones offers best outcomes for localised prostate cancer

The combination of radiotherapy and androgen deprivation therapy is more effective than radiotherapy alone for preventing disease recurrence in men with localised prostate cancer, according to research findings presented at the European Society for Radiotherapy and Oncology 33rd annual congress in Vienna, Austria.

14 Apr 2014

6 months of hormonal treatment in addition to radiotherapy improves outcome for prostate cancer

Vienna, Austria: Men with prostate cancer that is small and confined to the prostate gland but that is at risk of growing and spreading, do better if they are treated with radiotherapy combined with androgen deprivation therapy, which lowers their levels of the male hormone, testosterone, according to new research.

7 Apr 2014

Abiraterone can prolong overall survival and delay severe pain in prostate cancer patients

Abiraterone acetate (abiraterone for short, trade name: Zytiga) has been approved in Germany since December 2012 for men with metastatic prostate cancer that is not responsive to hormone blockade, who only have mild symptoms or so far none at all, and in whom chemotherapy is not yet indicated.

3 Jul 2013

Emotional stress can reduce prostate cancer drugs’ effectiveness

Not surprisingly, a cancer diagnosis creates stress. And patients with prostate cancer show higher levels of anxiety compared to other cancer patients. A new study by researchers at Wake Forest Baptist Medical Center indicates that stress is not just an emotional side effect of the diagnosis; it also can reduce the effectiveness of prostate cancer drugs and accelerate the development of prostate cancer.

29 Jan 2013

Adamis' APC-300 inhibits growth of prostate cancer cells

Adamis Pharmaceuticals Corporation announced today that in addition to activity in pancreatic cancer and its multiple modes of action, APC-300 significantly inhibits the growth of prostate cancer cells.

21 Jul 2011

Homosexual men with prostate cancer more likely to report problems with bicalutamide drug

Homosexual men taking bicalutamide for prostate cancer were much more likely to report sexual problems during treatment than heterosexual patients, according to a study in the July issue of the urology journal BJUI.

22 Jun 2011

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

Medivation, Inc. today provided a corporate update and reported its financial results for the second quarter ended June 30, 2010.

10 Aug 2010

KAPIDEX to be marketed as DEXILANT in the U.S.

Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX™ (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT™ (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.

5 Mar 2010